Fedotozine
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(2R)-N,N-dimethyl-2-phenyl-1-[(3,4,5-trimethoxybenzyl)oxy]-2-butanamine
|
|
| Clinical data | |
| Routes of administration |
Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 123618-00-8 133267-27-3 (tartrate) |
| ATC code | None |
| PubChem | CID 6918160 |
| ChemSpider | 5293373 |
| ChEMBL | CHEMBL2106275 |
| Chemical data | |
| Formula | C22H31NO4 |
| Molar mass | 373.486 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Fedotozine (INN; Jo-1196) is an opioid drug of the arylacetamide series which acts as a peripherally-specific, selective κ1-opioid receptor agonist with preference for the κ1A subtype.[1] It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials,[1][2][3] but ultimately development was discontinued and it was never marketed.
See also[edit]
References[edit]
- ^ a b Delvaux M (January 2001). "Pharmacology and clinical experience with fedotozine". Expert Opinion on Investigational Drugs. 10 (1): 97–110. doi:10.1517/13543784.10.1.97. PMID 11116283.
- ^ Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–68. doi:10.1517/13543784.6.10.1351. PMID 15989506.
- ^ Lembo A (2006). "Peripheral opioids for functional GI disease: a reappraisal". Digestive Diseases (Basel, Switzerland). 24 (1-2): 91–8. doi:10.1159/000090312. PMID 16699267.
